Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 31 entries
Sorted by: Best Match Show Resources per page
Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development.

Clinical and translational medicine

Lopez-Sanz L, Bernal S, Jimenez-Castilla L, Prieto I, La Manna S, Gomez-Lopez S, Blanco-Colio LM, Egido J, Martin-Ventura JL, Gomez-Guerrero C.
PMID: 34323424
Clin Transl Med. 2021 Jul;11(7):e463. doi: 10.1002/ctm2.463.

BACKGROUND: Abdominal aortic aneurysm (AAA), a degenerative vascular pathology characterized by permanent dilation of the aorta, is considered a chronic inflammatory disease involving innate/adaptive immunity. However, the functional role of antibody-dependent immune response against antigens present in the damaged...

Cite
Lopez-Sanz L, Bernal S, Jimenez-Castilla L, et al. Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development. Clin Transl Med. 2021;11(7):e463doi: 10.1002/ctm2.463.
Lopez-Sanz, L., Bernal, S., Jimenez-Castilla, L., Prieto, I., La Manna, S., Gomez-Lopez, S., Blanco-Colio, L. M., Egido, J., Martin-Ventura, J. L., & Gomez-Guerrero, C. (2021). Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development. Clinical and translational medicine, 11(7), e463. https://doi.org/10.1002/ctm2.463
Lopez-Sanz, Laura, et al. "Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development." Clinical and translational medicine vol. 11,7 (2021): e463. doi: https://doi.org/10.1002/ctm2.463
Lopez-Sanz L, Bernal S, Jimenez-Castilla L, Prieto I, La Manna S, Gomez-Lopez S, Blanco-Colio LM, Egido J, Martin-Ventura JL, Gomez-Guerrero C. Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development. Clin Transl Med. 2021 Jul;11(7):e463. doi: 10.1002/ctm2.463. PMID: 34323424; PMCID: PMC8255062.
Copy Download .nbib Format: NLM
Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs.

Drug metabolism and disposition: the biological fate of chemicals

Pike A, Jones B, Markandu R, O'Neill D.
PMID: 34135088
Drug Metab Dispos. 2021 Sep;49(9):736-742. doi: 10.1124/dmd.121.000409. Epub 2021 Jun 16.

Inconsistencies in pharmacokinetic parameters between individual animals in preclinical studies are a common occurrence. Often such differences between animals are simply accepted as experimental variability rather than as indications of specific differences in animal phenotype that could lead to...

Cite
Pike A, Jones B, Markandu R, et al. Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Drug Metab Dispos. 2021;49(9):736-742doi: 10.1124/dmd.121.000409.
Pike, A., Jones, B., Markandu, R., & O'Neill, D. (2021). Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Drug metabolism and disposition: the biological fate of chemicals, 49(9), 736-742. https://doi.org/10.1124/dmd.121.000409
Pike, Andy, et al. "Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs." Drug metabolism and disposition: the biological fate of chemicals vol. 49,9 (2021): 736-742. doi: https://doi.org/10.1124/dmd.121.000409
Pike A, Jones B, Markandu R, O'Neill D. Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Drug Metab Dispos. 2021 Sep;49(9):736-742. doi: 10.1124/dmd.121.000409. Epub 2021 Jun 16. PMID: 34135088.
Copy Download .nbib Format: NLM
Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation.

International journal of molecular sciences

Navarro S, Stegner D, Nieswandt B, Heemskerk JWM, Kuijpers MJE.
PMID: 35008781
Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010358.

In hemostasis and thrombosis, the complex process of thrombus formation involves different molecular pathways of platelet and coagulation activation. These pathways are considered as operating together at the same time, but this has not been investigated. The objective of...

Cite
Navarro S, Stegner D, Nieswandt B, et al. Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010358.
Navarro, S., Stegner, D., Nieswandt, B., Heemskerk, J. W. M., & Kuijpers, M. J. E. (2021). Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010358
Navarro, Stefano, et al. "Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010358
Navarro S, Stegner D, Nieswandt B, Heemskerk JWM, Kuijpers MJE. Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation. Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010358. PMID: 35008781; PMCID: PMC8745329.
Copy Download .nbib Format: NLM
Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Lutz HU.
PMID: 23801923
Transfus Med Hemother. 2012 Oct;39(5):321-7. doi: 10.1159/000342171. Epub 2012 Aug 27.

SUMMARY: Naturally occurring anti-band 3 antibodies (anti-band 3 NAbs) are directed against the 55-kDa chymotryptic fragment of the anion transport protein (band 3) of red blood cells (RBCs). They bind to senescent and oxidatively stressed RBCs and induce their...

Cite
Lutz HU. Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells. Transfus Med Hemother. 2012;39(5):321-7doi: 10.1159/000342171.
Lutz, H. U. (2012). Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 39(5), 321-7. https://doi.org/10.1159/000342171
Lutz, Hans U. "Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 39,5 (2012): 321-7. doi: https://doi.org/10.1159/000342171
Lutz HU. Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells. Transfus Med Hemother. 2012 Oct;39(5):321-7. doi: 10.1159/000342171. Epub 2012 Aug 27. PMID: 23801923; PMCID: PMC3678295.
Copy Download .nbib Format: NLM
Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway.

Biomolecules & therapeutics

Lu Y, Li X, Park YN, Kwon O, Piao D, Chang YC, Kim CH, Lee E, Son JK, Chang HW.
PMID: 25009699
Biomol Ther (Seoul). 2014 May;22(3):193-9. doi: 10.4062/biomolther.2014.038.

The aim of this study was to determine whether britanin, isolated from the flowers of Inula japonica (Inulae Flos), modulates the generation of allergic inflammatory mediators in activated mast cells. To understand the biological activity of britanin, the authors...

Cite
Lu Y, Li X, Park YN, et al. Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway. Biomol Ther (Seoul). 2014;22(3):193-9doi: 10.4062/biomolther.2014.038.
Lu, Y., Li, X., Park, Y. N., Kwon, O., Piao, D., Chang, Y. C., Kim, C. H., Lee, E., Son, J. K., & Chang, H. W. (2014). Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway. Biomolecules & therapeutics, 22(3), 193-9. https://doi.org/10.4062/biomolther.2014.038
Lu, Yue, et al. "Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway." Biomolecules & therapeutics vol. 22,3 (2014): 193-9. doi: https://doi.org/10.4062/biomolther.2014.038
Lu Y, Li X, Park YN, Kwon O, Piao D, Chang YC, Kim CH, Lee E, Son JK, Chang HW. Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway. Biomol Ther (Seoul). 2014 May;22(3):193-9. doi: 10.4062/biomolther.2014.038. PMID: 25009699; PMCID: PMC4060075.
Copy Download .nbib Format: NLM
FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils.

Journal of leukocyte biology

Ortiz-Stern A, Rosales C.
PMID: 29350792
J Leukoc Biol. 2005 May;77(5):787-799. doi: 10.1189/jlb.0504310.

The molecular stimuli involved in receptor-induced integrin activation are still poorly defined. We have investigated the role of receptors for the Fc portion of immunoglobulin G molecules (FcγR) on activation of integrins in human neutrophils. Cross-linking of FcγRIIA induced...

Cite
Ortiz-Stern A, Rosales C. FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils. J Leukoc Biol. 2005;77(5):787-799doi: 10.1189/jlb.0504310.
Ortiz-Stern, A., & Rosales, C. (2005). FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils. Journal of leukocyte biology, 77(5), 787-799. https://doi.org/10.1189/jlb.0504310
Ortiz-Stern, Alejandro, and Rosales, Carlos. "FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils." Journal of leukocyte biology vol. 77,5 (2005): 787-799. doi: https://doi.org/10.1189/jlb.0504310
Ortiz-Stern A, Rosales C. FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils. J Leukoc Biol. 2005 May;77(5):787-799. doi: 10.1189/jlb.0504310. PMID: 29350792.
Copy Download .nbib Format: NLM
Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis.

Blood

Weiss LJ, Manukjan G, Pflug A, Winter N, Weigel M, Nagler N, Kredel M, Lâm TT, Nieswandt B, Weismann D, Schulze H.
PMID: 33827131
Blood. 2021 Jun 03;137(22):3105-3115. doi: 10.1182/blood.2020009774.

Glycoprotein VI (GPVI), the platelet immunoreceptor tyrosine activating motif (ITAM) receptor for collagen, plays a striking role on vascular integrity in animal models of inflammation and sepsis. Understanding ITAM-receptor signaling defects in humans suffering from sepsis may improve our...

Cite
Weiss LJ, Manukjan G, Pflug A, et al. Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis. Blood. 2021;137(22):3105-3115doi: 10.1182/blood.2020009774.
Weiss, L. J., Manukjan, G., Pflug, A., Winter, N., Weigel, M., Nagler, N., Kredel, M., Lâm, T. T., Nieswandt, B., Weismann, D., & Schulze, H. (2021). Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis. Blood, 137(22), 3105-3115. https://doi.org/10.1182/blood.2020009774
Weiss, Lukas J, et al. "Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis." Blood vol. 137,22 (2021): 3105-3115. doi: https://doi.org/10.1182/blood.2020009774
Weiss LJ, Manukjan G, Pflug A, Winter N, Weigel M, Nagler N, Kredel M, Lâm TT, Nieswandt B, Weismann D, Schulze H. Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis. Blood. 2021 Jun 03;137(22):3105-3115. doi: 10.1182/blood.2020009774. PMID: 33827131.
Copy Download .nbib Format: NLM
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.

Oncoimmunology

Capuano C, Pighi C, Molfetta R, Paolini R, Battella S, Palmieri G, Giannini G, Belardinilli F, Santoni A, Galandrini R.
PMID: 28405525
Oncoimmunology. 2017 Feb 10;6(3):e1290037. doi: 10.1080/2162402X.2017.1290037. eCollection 2017.

Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcγRIIIA/CD16, represents one of the main mechanisms by which therapeutic antibodies (mAbs) mediate their antitumor effects. Besides ADCC,...

Cite
Capuano C, Pighi C, Molfetta R, et al. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production. Oncoimmunology. 2017;6(3):e1290037doi: 10.1080/2162402X.2017.1290037.
Capuano, C., Pighi, C., Molfetta, R., Paolini, R., Battella, S., Palmieri, G., Giannini, G., Belardinilli, F., Santoni, A., & Galandrini, R. (2017). Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production. Oncoimmunology, 6(3), e1290037. https://doi.org/10.1080/2162402X.2017.1290037
Capuano, Cristina, et al. "Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production." Oncoimmunology vol. 6,3 (2017): e1290037. doi: https://doi.org/10.1080/2162402X.2017.1290037
Capuano C, Pighi C, Molfetta R, Paolini R, Battella S, Palmieri G, Giannini G, Belardinilli F, Santoni A, Galandrini R. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production. Oncoimmunology. 2017 Feb 10;6(3):e1290037. doi: 10.1080/2162402X.2017.1290037. eCollection 2017. PMID: 28405525; PMCID: PMC5384385.
Copy Download .nbib Format: NLM
Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in .

Antioxidants (Basel, Switzerland)

Tsamesidis I, Reybier K, Marchetti G, Pau MC, Virdis P, Fozza C, Nepveu F, Low PS, Turrini FM, Pantaleo A.
PMID: 32824055
Antioxidants (Basel). 2020 Aug 14;9(8). doi: 10.3390/antiox9080753.

Although artemisinin-based combination therapies (ACTs) treat

Cite
Tsamesidis I, Reybier K, Marchetti G, et al. Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in . Antioxidants (Basel). 2020;9(8)doi: 10.3390/antiox9080753.
Tsamesidis, I., Reybier, K., Marchetti, G., Pau, M. C., Virdis, P., Fozza, C., Nepveu, F., Low, P. S., Turrini, F. M., & Pantaleo, A. (2020). Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in . Antioxidants (Basel, Switzerland), 9(8), . https://doi.org/10.3390/antiox9080753
Tsamesidis, Ioannis, et al. "Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in ." Antioxidants (Basel, Switzerland) vol. 9,8 (2020). doi: https://doi.org/10.3390/antiox9080753
Tsamesidis I, Reybier K, Marchetti G, Pau MC, Virdis P, Fozza C, Nepveu F, Low PS, Turrini FM, Pantaleo A. Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in . Antioxidants (Basel). 2020 Aug 14;9(8). doi: 10.3390/antiox9080753. PMID: 32824055; PMCID: PMC7464437.
Copy Download .nbib Format: NLM
The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src-related tyrosine kinases.

Journal of leukocyte biology

Huang ZY, Hunter S, Kim MK, Chien P, Worth RG, Indik ZK, Schreiber AD.
PMID: 29350785
J Leukoc Biol. 2004 Aug;76(2):491-499. doi: 10.1189/jlb.1103562.

There are important differences in signaling between the Fc receptor for immunoglobulin G (IgG) FcγRIIA, which uses the Ig tyrosine-activating motif (ITAM) within its own cytoplasmic domain, and FcγRI, which transmits signals by means of an ITAM located within...

Cite
Huang ZY, Hunter S, Kim MK, et al. The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src-related tyrosine kinases. J Leukoc Biol. 2004;76(2):491-499doi: 10.1189/jlb.1103562.
Huang, Z. Y., Hunter, S., Kim, M. K., Chien, P., Worth, R. G., Indik, Z. K., & Schreiber, A. D. (2004). The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src-related tyrosine kinases. Journal of leukocyte biology, 76(2), 491-499. https://doi.org/10.1189/jlb.1103562
Huang, Zhen-Yu, et al. "The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src-related tyrosine kinases." Journal of leukocyte biology vol. 76,2 (2004): 491-499. doi: https://doi.org/10.1189/jlb.1103562
Huang ZY, Hunter S, Kim MK, Chien P, Worth RG, Indik ZK, Schreiber AD. The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src-related tyrosine kinases. J Leukoc Biol. 2004 Aug;76(2):491-499. doi: 10.1189/jlb.1103562. PMID: 29350785.
Copy Download .nbib Format: NLM
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.

Oncotarget

Lamb DJ, Rust A, Rudisch A, Glüxam T, Harrer N, Machat H, Christ I, Colbatzky F, Wernitznig A, Osswald A, Sommergruber W.
PMID: 32292575
Oncotarget. 2020 Apr 07;11(14):1257-1272. doi: 10.18632/oncotarget.27545. eCollection 2020 Apr 07.

SYK has been reported to possess both tumour promotor and repressor activities and deletion has been linked to a pro-proliferative / pro-invasive phenotype in breast tumours. It is unclear whether this is a consequence of protein deletion or loss...

Cite
Lamb DJ, Rust A, Rudisch A, et al. Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells. Oncotarget. 2020;11(14):1257-1272doi: 10.18632/oncotarget.27545.
Lamb, D. J., Rust, A., Rudisch, A., Glüxam, T., Harrer, N., Machat, H., Christ, I., Colbatzky, F., Wernitznig, A., Osswald, A., & Sommergruber, W. (2020). Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells. Oncotarget, 11(14), 1257-1272. https://doi.org/10.18632/oncotarget.27545
Lamb, David J, et al. "Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells." Oncotarget vol. 11,14 (2020): 1257-1272. doi: https://doi.org/10.18632/oncotarget.27545
Lamb DJ, Rust A, Rudisch A, Glüxam T, Harrer N, Machat H, Christ I, Colbatzky F, Wernitznig A, Osswald A, Sommergruber W. Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells. Oncotarget. 2020 Apr 07;11(14):1257-1272. doi: 10.18632/oncotarget.27545. eCollection 2020 Apr 07. PMID: 32292575; PMCID: PMC7147091.
Copy Download .nbib Format: NLM
Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.

Scientific reports

Novikov FN, Panova MV, Titov IY, Stroylov VS, Stroganov OV, Chilov GG.
PMID: 34848799
Sci Rep. 2021 Nov 30;11(1):23120. doi: 10.1038/s41598-021-02568-6.

The pathophysiology of osteoarthritis (OA) includes the destruction of subchondral bone tissue and inflammation of the synovium. Thus, an effective disease-modifying treatment should act on both of these pathogenetic components. It is known that cSrc kinase is involved in...

Cite
Novikov FN, Panova MV, Titov IY, et al. Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis. Sci Rep. 2021;11(1):23120doi: 10.1038/s41598-021-02568-6.
Novikov, F. N., Panova, M. V., Titov, I. Y., Stroylov, V. S., Stroganov, O. V., & Chilov, G. G. (2021). Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis. Scientific reports, 11(1), 23120. https://doi.org/10.1038/s41598-021-02568-6
Novikov, F N, et al. "Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis." Scientific reports vol. 11,1 (2021): 23120. doi: https://doi.org/10.1038/s41598-021-02568-6
Novikov FN, Panova MV, Titov IY, Stroylov VS, Stroganov OV, Chilov GG. Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis. Sci Rep. 2021 Nov 30;11(1):23120. doi: 10.1038/s41598-021-02568-6. PMID: 34848799; PMCID: PMC8632988.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 31 entries